[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603141":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":36,"locations":28,"responsibleParty":43,"collaborators":28,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":28,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":28,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":67,"whyStopped":28,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":28},{"fullName":5,"class":6},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Initial Phase","ACTIVE_COMPARATOR","Whole Gland 36.25Gy\u002F5Rx",[13],"Radiation: MR-Guided SBRT",{"label":15,"type":16,"description":17,"interventionNames":18},"Study Phase","EXPERIMENTAL","Whole Gland 27Gy\u002F2Rx",[13],{"label":20,"type":16,"description":21,"interventionNames":22},"Final Phase","Asymmetrical Whole Gland 27Gy\u002F2Rx",[13],[24],{"type":25,"name":26,"description":26,"armGroupLabels":27,"otherNames":28},"RADIATION","MR-Guided SBRT",[20,9,15],null,[30,34],{"name":31,"affiliation":32,"role":33},"Rafael Martínez-Monge, M.D.","Clínica Universidad de Navarra","PRINCIPAL_INVESTIGATOR",{"name":35,"affiliation":32,"role":33},"Luis Fuertes, M.D.",[37],{"name":38,"role":39,"phone":40,"phoneExt":41,"email":42},"Beatriz Ramos Aguirre, M.S.","CONTACT","+34948255400","2772","ucicec@unav.es",{"type":44,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100603141","mri-guided-ultrahypofractionated-sbrt-prostate-program-100603141",false,"NCT07132658","MRI-guided Ultrahypofractionated SBRT Prostate Program","PROJECT#2: MRI-guided Local SBRT Prostate Program","Optimal Inclusion Criteria\n\n* Patients with low to favorable intermediate-risk prostate cancer as per the NCCN stratification criteria .\n* No prior radiation therapy to the target areas\n* Expected patient survival \\>5 years\n* Patient able to undergo a MRI exam\n\nCautionary Inclusion Criteria\n\n* Suboptimal candidates for high-dose therapy such as elderly, frail patients or patients with large volume glands (i.e, \\>60cm3) or extensive TURP in the prior 6-12 months should be considered cautionary indications.\n* Patients with higher risk but low volume disease not candidates for ENI may be treated on an individual basis\n\nExclusion Criteria\n\n* Prior radiation therapy to the target areas\n* Expected patient survival below 5 years\n* Patient unable to undergo a MRI exam","MALE","18 Years","85 Years",{"count":56,"type":57},40,"ESTIMATED","INTERVENTIONAL",[60],"NA","The goal of this clinical trial is to learn if the use of MRI-guided asymmetric ultrahipofractionated irradiation (2 fractions with dose increase in the tumor areas and dose sparing in urethra, rectum and neurovascular bundles) produces similar results in terms of local control and complications to standard 5-fraction SBRT.",[63],"Prostate Cancer",[63,65,66],"NCCN Low Risk","NCCN Favorable Intermediate Risk","NOT_YET_RECRUITING","2025-08-12",{"date":70,"type":71},"2025-08-20","ACTUAL",{"date":73,"type":57},"2025-10-01",{"date":75,"type":57},"2030-06-30",{"name":5,"class":6}]